This content is sourced exclusively from TruthTides clinical reference data and does not constitute medical advice.
Clinical Question
Does the administration of MK-677 (Ibutamoren) effectively stimulate growth hormone (GH) and insulin-like growth factor 1 (IGF-1) secretion, and what are the associated changes in body composition and metabolic markers in clinical populations?
Evidence Snapshot
- Evidence Grade: B
- Study Type: 2-year Randomized Controlled Trial (RCT)
- Classification: Non-peptide, small-molecule ghrelin mimetic (selective GHS-R1a agonist)
- Primary Outcomes: Restoration of GH/IGF-1 levels; +1.1kg increase in fat-free mass (FFM)
- Secondary Outcomes: Elevated fasting glucose; no significant effect on cortisol levels
- Regulatory Status: Not FDA-approved; Investigational New Drug (IND) status in the US
What the Research Shows
The primary evidence supporting MK-677 stems from a 2-year randomized controlled trial. This study demonstrated that MK-677 successfully restored GH and IGF-1 levels. In terms of body composition, participants experienced an average increase of 1.1kg in fat-free mass (FFM).
However, clinical outcomes have been mixed depending on the indication. While the compound effectively modulates the GH axis, it failed in clinical trials for the treatment of Alzheimer's disease. Furthermore, the metabolic profile suggests notable shifts in glucose regulation. Data indicates that administration of MK-677 raises fasting glucose levels and results in worsened insulin sensitivity over the study period.
Mechanism
MK-677 is an orally active, non-peptide compound that functions as a selective ghrelin receptor (GHS-R1a) agonist. It acts as a ghrelin mimetic to stimulate the pulsatile release of growth hormone. This mechanism leads to a sustained elevation of IGF-1. Unlike some other secretagogues, MK-677 does not significantly affect cortisol levels. Due to its chemical structure and pharmacokinetic profile, it possesses a 24-hour oral half-life, which enables once-daily dosing.
Limitations of the Evidence
Despite extensive study, several significant gaps remain in the clinical understanding of MK-677. While increases in fat-free mass (FFM) have been recorded, it is hypothesized that these gains may partly reflect an increase in intracellular water rather than purely skeletal muscle hypertrophy.
Metabolic safety remains a primary concern, as the evidence clearly shows that the compound raises fasting glucose and impairs insulin sensitivity. Additionally, although the compound was evaluated for neurological applications, it failed to show efficacy in an Alzheimer’s trial. From a regulatory perspective, MK-677 is not FDA-approved for any clinical indication, though it currently holds Investigational New Drug (IND) status in the United States.
Clinical Takeaway
MK-677 is a potent, orally active GHS-R1a agonist capable of restoring GH/IGF-1 levels and increasing fat-free mass over a 2-year period. However, its clinical utility is complicated by its tendency to worsen insulin sensitivity and raise fasting glucose. It is not currently approved for medical use, and its impact on body composition may be influenced by changes in intracellular water retention.
Sources
- TruthTides Database: MK-677 (Ibutamoren) [Grade: B]
- Two-year RCT: GH/IGF-1 and FFM outcomes
- Regulatory Data: US IND status documentation
Referenced Peptides
This content was generated from TruthTides clinical reference data. It does not constitute medical advice. Always consult a qualified healthcare provider.